These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
627 related articles for article (PubMed ID: 35754218)
21. Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Gao X; Wang C; Yu Y; Singh D; Yang L; Zhou Z World J Surg Oncol; 2020 Nov; 18(1):304. PubMed ID: 33228677 [TBL] [Abstract][Full Text] [Related]
22. Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer: A Comparison of Short- and Long-term Oncologic Outcomes. Goffredo P; Khan A; Mott SL; Jensen CC; Madoff RD; Gaertner WB; You YN; Hassan I Ann Surg; 2022 Dec; 276(6):e819-e824. PubMed ID: 34353995 [TBL] [Abstract][Full Text] [Related]
23. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992 [TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752 [TBL] [Abstract][Full Text] [Related]
25. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis. Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y Front Oncol; 2023; 13():1177557. PubMed ID: 37228495 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis. Xiong K; Bao T; Cao Y; Hu W; Deng J; Chen J; Xiao T Int J Colorectal Dis; 2023 Apr; 38(1):89. PubMed ID: 37004572 [TBL] [Abstract][Full Text] [Related]
27. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM). Capelli G; De Simone I; Spolverato G; Cinquini M; Moschetti I; Lonardi S; Masi G; Carlomagno C; Corsi D; Luppi G; Gambacorta MA; Valvo F; Cannizzaro R; Grillo F; Barbaro B; Restivo A; Messina M; Pastorino A; Aschele C; Pucciarelli S J Gastrointest Surg; 2020 Sep; 24(9):2150-2159. PubMed ID: 32394125 [TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial. Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032 [TBL] [Abstract][Full Text] [Related]
30. Current status of total neoadjuvant therapy for locally advanced rectal cancer. Feng W; Yu B; Zhang Z; Li J; Wang Y Asia Pac J Clin Oncol; 2022 Dec; 18(6):546-559. PubMed ID: 34818447 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial. Mei WJ; Wang XZ; Li YF; Sun YM; Yang CK; Lin JZ; Wu ZG; Zhang R; Wang W; Li Y; Zhuang YZ; Lei J; Wan XB; Ren YK; Cheng Y; Li WL; Wang ZQ; Xu DB; Mo XW; Ju HX; Ye SW; Zhao JL; Zhang H; Gao YH; Zeng ZF; Xiao WW; Zhang XP; Zhang X; Xie E; Feng YF; Tang JH; Wu XJ; Chen G; Li LR; Lu ZH; Wan DS; Bei JX; Pan ZZ; Ding PR Ann Surg; 2023 Apr; 277(4):557-564. PubMed ID: 36538627 [TBL] [Abstract][Full Text] [Related]
32. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis. Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577 [TBL] [Abstract][Full Text] [Related]
34. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919 [TBL] [Abstract][Full Text] [Related]
35. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909 [TBL] [Abstract][Full Text] [Related]
36. [The safety and efficacy of radical surgery after modified total neoadjuvant therapy for locally advanced rectal cancer]. Zhang L; Yu L; Wu YL; Zhang QQ; Shen SH; Li DD; Fang H; Yang L; Zhang HZ Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):501-506. PubMed ID: 32575948 [No Abstract] [Full Text] [Related]
37. Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials. Donnelly M; Ryan OK; Ryan ÉJ; Creavin B; O'Reilly M; McDermott R; Kennelly R; Hanly A; Martin ST; Winter DC Br J Surg; 2023 Sep; 110(10):1316-1330. PubMed ID: 37330950 [TBL] [Abstract][Full Text] [Related]
38. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy]. Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306 [No Abstract] [Full Text] [Related]
39. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis. Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563 [TBL] [Abstract][Full Text] [Related]
40. Prolonged interval to surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysis of randomized controlled trials. Owens PW; Saeed M; McCawley N; Loughlin P; Kearney DE; Burke JP; McNamara DA; Sahebally SM Surgeon; 2024 Jun; 22(3):166-173. PubMed ID: 38521683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]